Key result
ACE inhibitors remain the drugs of first choice for treating major cardiovascular diseases because they not only reduce blood pressure but also protect and potentiate kinins, reducing morbidity and mortality.
Design
Review
Authors
Loading...
May support ACE inhibitor preference in CVD; leaves open need for prospective trials isolating kinin effects.
This review highlights that the kallikrein-kinin system is the dominant mechanism counteracting the hyperactive renin-angiotensin system, explaining the clinical superiority of ACE inhibitors over ARBs in reducing cardiovascular morbidity and mortality.
Regoli et al. (2017) conducted a review in Cardiovascular diseases and hypertension. ACE inhibitors vs. Sartans and Ang (1-7) was evaluated. ACE inhibitors remain the drugs of first choice for treating major cardiovascular diseases because they not only reduce blood pressure but also protect and potentiate kinins, reducing morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: